Abstracts

Butyrate Reduces Pathobiont-Associated HIV-1 Infection and Activation of Gut T Cell

Background: We previously reported that untreated chronic HIV-1 infection is associated with an altered intestinal microbiome that was linked to mucosal and systemic inflammation. HIV-1-infected (HIV+) subjects had increased abundances of pathobionts (e.g. Prevotella) and decreased abundances of bacterial families that contain butyrate-producing bacterial species (BPB). Butyrate is a short chain fatty acid important in…

Maraviroc Does Not Induce Changes in the Gut Microbiome of HIV-Infected Individuals

Background: HIV preferentially depletes CD4 T cells in the gut-associated lymphoid tissue during acute infection, likely associated with high levels of CCR5 expression. Maraviroc (MVC) blocks HIV entry by binding CCR5. The consequences of MVC treatment on the gut microbiome have not been investigated. Here, we evaluated the impact of antiretroviral treatment (ART) plus MVC…

Impact of 2 Antiretroviral Regimens on Fecal Microbial Diversity and Composition

Background: Reports have shown that microbial composition of individuals on antiretroviral therapy (ART) is different from that of non-HIV-infected individuals. However, the degree to which ART restores the microbial composition remains unclear. The aim of this study was to determine the effect of two types of ART regimens: Efavirenz-based regimen (EFV) and protease inhibitor-based regimen…

Targeting Gut Dysbiosis With Prebiotics and Glutamine in HIV-Infected Subjects

Background: Altered interplay between gut mucosa and dysbiotic microbes during treated HIV infection has been linked to chronic immune dysfunction. Studies evaluating the effects of therapies aimed at shaping gut microbiota in HIV-infected subjects are needed. Methods: In this study, 45 subjects including 12 HIV+ viremic untreated (VU), 24 ART-treated virally suppressed (AT) and 9…

Impact of Mucosal Immunity and HIV Persistence on CD4/CD8 Ratio After ART Initiation

Background: The CD4/CD8 ratio correlates with persistent T-cell dysfunction and mortality. We examined the impact of changes (Δ) in the HIV reservoir, systemic inflammation/bacterial translocation and mucosal immunity following ART initiation on CD4/CD8 ratio. Methods: 33 ART naïve HIV subjects were randomized to efavirenz, maraviroc or maraviroc+raltegravir, each with tenofovir/emtricitabine. Colon and duodenal biopsies were…

Monocyte/Macrophage Activation and Recruitment to Mucosal Sites in SIV Pathogenesis

Background: Monocytes/macrophages (Mo/Ma) assume unique functions in HIV infection, being linked to microbial translocation, immune activation and inflammation (IA/INFL). We compared the fate of Mo/Ma in pathogenic, nonpathogenic and controlled SIVsab infection of pigtailed macaque (PTM), African green monkey (AGM) and rhesus macaques (RM) to better define their role in SIV pathogenesis. Methods: We assessed…

Rectal Tenofovir Gel Usage Is Associated With Changes in the Mucosal Proteome

Background: After the success of the CAPRISA-004 clinical trial showing efficacy of vaginally-applied tenofovir (TFV)-based gels at preventing HIV infection, rectal formulations are currently being explored as a prevention option. However, further research is needed to characterize the safety of rectal microbicide gels. Standard mucosal safety tests, such as inflammatory cytokine measurements, may miss important…

Links Between Systemic and Mucosal Immunity in Treated HIV Infection

Background: Recent data suggest that biomarkers of gut epithelial barrier dysfunction, bacterial translocation and inflammation predict mortality and are possibly linked to altered gut immunity. A better understanding of the underlying mechanisms might help to design interventions targetting chronic inflammation. Methods: We assessed biomarkers of inflammation (IL-6) and gut barrier (lipoteichoic acid [LTA], sCD14 and…

No Impact of Early Intensified Antiretroviral Therapy on Gut Immune Reconstitution

Background: HIV infection is characterized by reduced mucosal Th22 and Th17 cell numbers and function, which contribute to microbial translocation and inflammation. Standard antiretroviral therapy (ART) is slow to reverse these mucosal defects, and the resulting persistent inflammation is linked to serious non-AIDS illnesses (SNAs). We examined whether ART intensification with maraviroc and raltegravir during…